Becton DickinsonXSWX:BDX +0.53%77 5-Year Yield-on-Cost % is 1.73 as of Jul. 11, 2026, which is 25% below its 10-year median of 2.32. GuruFocus rates XSWX:BDX with a GF Score™ of 77/100 and a GF Value™ of CHF152.77. The stock has 3 warning signs investors should review. Among 327 Medical Devices & Instruments companies, Becton Dickinson ranks better than 65.14% on this metric.
Becton Dickinson's yield on cost for the quarter that ended in Mar. 2026 was 1.73.
The historical rank and industry rank for Becton Dickinson's 5-Year Yield-on-Cost % or its related term are showing as below:
XSWX:BDX'
s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 1.89 Med: 2.32 Max: 3.94
Current: 1.73
During the past 13 years, Becton Dickinson's highest Yield on Cost was 3.94. The lowest was 1.89. And the median was 2.32.
XSWX:BDX's 5-Year Yield-on-Cost % is ranked better than 65.14% of 327
companies
in the Medical Devices & Instruments industry
Industry Median: 2.34
vs XSWX:BDX: 1.73
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Becton Dickinson 5-Year Yield-on-Cost % Related Terms
XSWX:BDX vs MDLN, RMD, WST: 5-Year Yield-on-Cost % Comparison
For the Medical Instruments & Supplies subindustry, Becton Dickinson's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Becton Dickinson 5-Year Yield-on-Cost % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Becton Dickinson's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Becton Dickinson's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Becton Dickinson (XSWX:BDX) has a 5-Year Yield-on-Cost % of 1.73 as of Jul. 11, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Becton Dickinson and its competitors. This is 25% below median its historical median of 2.32. Over the past decade, Becton Dickinson's 5-Year Yield-on-Cost % has ranged from 1.89 to 3.94. According to the industry distribution chart, Becton Dickinson ranks #114 out of 327 companies in the Medical Devices & Instruments industry, placing it in the top 34.9%.
Is Becton Dickinson's 5-Year Yield-on-Cost % too high?
Becton Dickinson's current 5-Year Yield-on-Cost % of 1.73 is 25% below median its 10-year median of 2.32. Over the past 10 years, this metric has ranged from a low of 1.89 to a high of 3.94. The Medical Devices & Instruments industry median 5-Year Yield-on-Cost % is 2.34. Becton Dickinson's value of 1.73 is 26.1% below this industry median. Based on the distribution chart, Becton Dickinson ranks #114 out of 327 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Becton Dickinson has a GF Score™ of 77/100, reflecting its overall financial health beyond just this single metric.
How does Becton Dickinson's 5-Year Yield-on-Cost % compare to MDLN and RMD?
According to the Medical Devices & Instruments industry distribution chart, Becton Dickinson ranks #114 out of 327 companies for 5-Year Yield-on-Cost %. This puts Becton Dickinson in the upper half of its industry. The industry median 5-Year Yield-on-Cost % is 2.34. Becton Dickinson's value of 1.73 is 26.1% below this benchmark. Historically, Becton Dickinson's own 5-Year Yield-on-Cost % has ranged from 1.89 to 3.94 over the past decade. While the company's 10-year median is 2.32 vs. the industry median of 2.34, Becton Dickinson has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Medical Devices & Instruments company?
The median 5-Year Yield-on-Cost % among Medical Devices & Instruments companies is 2.34, based on 327 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Becton Dickinson's current 5-Year Yield-on-Cost % of 1.73 is 26.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Becton Dickinson and its competitors. For the Medical Devices & Instruments industry, the median 5-Year Yield-on-Cost % is 2.34 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Becton Dickinson's current 5-Year Yield-on-Cost % is 1.73, which is 25% below median its own 10-year median of 2.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Becton Dickinson stock overvalued right now?
Becton Dickinson (XSWX:BDX) has a current 5-Year Yield-on-Cost % of 1.73. The stock's GF Value™ is CHF152.77, compared to a current price of CHF122.44 — trading 19.9% below its estimated fair value. The current 5-Year Yield-on-Cost % is 1.73, which is 25% below median its 10-year median of 2.32 and 26.1% below the Medical Devices & Instruments industry median of 2.34. Becton Dickinson's overall GF Score™ is 77/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Becton Dickinson (XSWX:BDX), the current 5-Year Yield-on-Cost % is 1.73 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Becton Dickinson (XSWX:BDX) Overvalued in 2026?
Based on GuruFocus' analysis, Becton Dickinson stock appears to be undervalued.
The current stock price of CHF122.44 is trading 19.9% below its estimated GF Value™ of CHF152.77.
Key valuation signals for XSWX:BDX:
5-Year Yield-on-Cost %: 1.73 (25% below median its 10-year median of 2.32)
GF Value™: CHF152.77 vs. price of CHF122.44 (19.9% below fair value)
Industry Position: 26.1% below the Medical Devices & Instruments median (#114 of 327)
No single metric tells the full story. See the XSWX:BDX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Becton Dickinson operates in four business units. Medical essentials (35% of total sales) includes the legacy medical surgical unit, which sells catheters, syringes, and infection prevention products. Connected care (24%) core products include the Alaris infusion pump, Pyxis dispensing system, and pharmacy automation platforms. Biopharma systems (13%) produces prefillable syringes and autoinjectors. Interventional (29%) is composed of the surgery, peripheral vascular, and urology segments. More than 60% of revenue comes from the United States.
77GF Score
Get the complete analysis for XSWX:BDX
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:BDX has been successfully added to your 